// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Targeted intraoperative radiotherapy tumour bed boost during breast conserving surgery after neoadjuvant chemotherapy.

Hans-Christian Kolberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Heterogeneity of variance in objective measures of aesthetic outcome associated with whole breast external beam radiotherapy compared with intraoperative radiotherapy in early breast cancer.

Norman R. Williams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A combined HER3-EGFR score in triple-negative breast cancer: racial differences.

Angela Ogden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Delays in breast cancer presentation and diagnosis in Nigeria.

Elima E. Jedy-Agba - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cancer control in Latin America (LA) and the Caribbean: 2015 update.

Diego Touya - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Sequential immune checkpoint inhibition with concurrent bevacizumab for relapsed glioblastoma: A single centre experience.

Nicholas Fraser Brown - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Pembrolizumab

Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).

Samuel John Harris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

Thrombosis in a population of phase I trial patients.

Alan D. Smith - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

miRNA-loaded exosome-like microparticles as targeted cancer therapy.

Marianna Proklopi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Study of the effect of novel anticancer agent oncamex on gene expression profiles of preclinical breast cancer models.

Carlos Martinez-Perez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Budgetary impact of lipegfilgrastim to the Brazilian public healthcare system.

Agota Szende - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lipegfilgrastim

A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.

Mariane Sousa Fontes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

2-OHOA

Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

R Donald Harvey - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rosuvastatin

Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.

Keyvan Rezai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

onapristone

Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).

Karthick Vishwanathan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Itraconazole

Concomitant use of antiacids in patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib therapy.

Razwan Abd Razak - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Phase 1 study of E7046, an inhibitor of the PGE2 receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291).

David S. Hong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Unspecified Cancer

Dinoprostone

Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600mutant tumors.

Noelia Nebot - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dabrafenib Mesylate

Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.

Michele Moschetta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Targeting OX40 by monoclonal antibody PF-04518600 to enhance T cell functions and inhibit tumor growth.

Hua Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved